Blau Farmacêutica S.A
Blau Farmacêutica S.A., a pharmaceutical company provides drug products in Brazil, Argentina, Chile, Colombia, Uruguay, Ecuador, Peru, and the United States. Its products cover various areas, such as immunology, hematology, oncology, nephrology, infectology, and anesthesiology. The company offers uterine stimulator, antirheumatic, anaesthetics, antibiotics, feminine health care, biopharmaceutical… Read more
Blau Farmacêutica S.A (BLAU3) - Total Liabilities
Latest total liabilities as of September 2025: R$1.29 Billion BRL
Based on the latest financial reports, Blau Farmacêutica S.A (BLAU3) has total liabilities worth R$1.29 Billion BRL as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Blau Farmacêutica S.A - Total Liabilities Trend (2013–2024)
This chart illustrates how Blau Farmacêutica S.A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Blau Farmacêutica S.A Competitors by Total Liabilities
The table below lists competitors of Blau Farmacêutica S.A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
MedPeerInc
PINK:MDPEF
|
USA | $5.02 Billion |
|
Melhus Sparebank
OL:MELG
|
Norway | Nkr10.35 Billion |
|
Soken Chemical & Engineering Co. Ltd
MU:SOQ
|
Germany | €15.10 Billion |
|
Rorze Systems Corporation
KQ:071280
|
Korea | ₩25.44 Billion |
|
Zeotech Ltd
AU:ZEO
|
Australia | AU$1.91 Million |
|
Burcelik Bursa Celik Dokum Sanayi AS
IS:BURCE
|
Turkey | TL70.44 Million |
|
HMS Bergbau AG
XETRA:HMU
|
Germany | €175.91 Million |
|
Infant Bacterial Therapeutics AB (publ)
ST:IBT-B
|
Sweden | Skr53.87 Million |
Liability Composition Analysis (2013–2024)
This chart breaks down Blau Farmacêutica S.A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.90 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.55 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Blau Farmacêutica S.A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Blau Farmacêutica S.A (2013–2024)
The table below shows the annual total liabilities of Blau Farmacêutica S.A from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | R$1.26 Billion | +19.16% |
| 2023-12-31 | R$1.06 Billion | +55.37% |
| 2022-12-31 | R$681.11 Million | -1.74% |
| 2021-12-31 | R$693.16 Million | -34.07% |
| 2020-12-31 | R$1.05 Billion | +122.41% |
| 2019-12-31 | R$472.69 Million | +27.47% |
| 2018-12-31 | R$370.82 Million | +62.90% |
| 2017-12-31 | R$227.63 Million | +4.31% |
| 2016-12-31 | R$218.24 Million | -0.60% |
| 2015-12-31 | R$219.55 Million | +20.95% |
| 2014-12-31 | R$181.53 Million | +7.88% |
| 2013-12-31 | R$168.27 Million | -- |